NDA 208854 · Bdsi
Symproic
Naldemedine Tosylate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jul 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 23, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 3 recruiting
FAERS reports
1,662
1,228 serious, 465 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 25, 2025.
SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. SYMPROIC is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation ( 1 )
Mechanism: Naldemedine is an opioid antagonist with binding affinities for mu-, delta-, and kappa-opioid receptors. Naldemedine functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naldemedine is a derivative of naltrexone to which a side chain has been added that increases the molecular weight and the polar surface area, thereby reducing its ability to cross the blood-brain barrier (BBB). Naldemedine is also a substrate of the P-glycoprotein (P-gp) efflux transporter. Based on these...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SYMPROIC · NALDEMEDINE TOSYLATE EQ 0.2MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Naldemedine" as an intervention, any sponsor and status, largest first.
- Long Term Safety of NaldemedinePivotal-lookingCompleted
ShionogiIndustry
NCT01965652 · 1,246 participants · Start Sep 24, 2013 · Primary completion Jan 12, 2016
Drug: Naldemedine; Placebo · For: Opioid-induced Constipation
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 186 sites in all
- Efficacy and Safety of Naldemedine in Treating Opioid-induced ConstipationPivotal-lookingCompleted
ShionogiIndustry
NCT01993940 · 553 participants · Start Nov 4, 2013 · Primary completion Jun 9, 2015
Drug: Naldemedine; Placebo · For: Opioid-induced Constipation
Sites: Birmingham, Alabama; Homewood, Alabama; Goodyear, Arizona · 49 sites in all
- Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced ConstipationPivotal-lookingCompleted
ShionogiIndustry
NCT01965158 · 547 participants · Start Aug 29, 2013 · Primary completion Jan 22, 2015
Drug: Naldemedine; Placebo · For: Opioid-induced Constipation
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 65 sites in all
- A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid TherapyPivotal-lookingCompleted
ShionogiIndustry
NCT01443403 · 244 participants · Start Aug 17, 2011 · Primary completion Aug 22, 2012
Drug: Placebo; Naldemedine · For: Opioid-induced Constipation
Sites: Phoenix, Arizona; Sun Lakes, Arizona; Little Rock, Arkansas · 49 sites in all
- Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON StudyPivotal-lookingCompleted
International University of Health and WelfareAcademic, hospital or other
NCT07038551 · 120 participants · Start Jun 20, 2025 · Primary completion Feb 13, 2026
Drug: Naldemedine; Placebo · For: Opioid-Induced Nausea and Vomitting(OINV)
Sites: Toyohashi, Japan; Narita, Japan; Iizuka, Japan · 20 sites in all
- Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute PancreatitisPivotal-lookingStatus unknown
Asbjørn Mohr DrewesAcademic, hospital or other
NCT04966559 · 74 participants · Start Jan 12, 2022 · Primary completion Mar 30, 2024
Drug: Placebo treatment; Naldemedine 0.2 MG Oral Tablet · For: Pancreatitis, Acute
Sites: Aalborg, Denmark; Bispebjerg, Denmark; Hvidovre, Denmark · 5 sites in all
ShionogiIndustry
NCT01122030 · 72 participants · Start May 19, 2010 · Primary completion Feb 23, 2011
Drug: Naldemedine; Placebo · For: Opioid Induced Bowel Dysfunction
Sites: Salt Lake City, Utah
- Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving OpioidsRecruiting
ShionogiIndustry
NCT05588323 · 24 participants (planned) · Start Jan 4, 2023 · Primary completion Jun 15, 2028
Drug: Naldemedine · For: Opioid-Induced Constipation (OIC)
Sites: Tirana, Albania; Yerevan, Armenia; Brussels, Belgium · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea191
- nausea132
- constipation111
- drug ineffective111
- malignant neoplasm progression98
- abdominal pain92
- interstitial lung disease81
- decreased appetite78
- malaise69
- anaemia65
- pyrexia64
- vomiting60
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2017 | 65 |
| 2018 | 371 |
| 2019 | 196 |
| 2020 | 132 |
| 2021 | 134 |
| 2022 | 189 |
| 2023 | 143 |
| 2024 | 156 |
| 2025 | 168 |
| 2026 | 101 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Symproic (Naldemedine Tosylate)
2024 spending
$9.8M
Beneficiaries
4,141
18,888 claims
Per beneficiary
$2,356
$15.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,602,455 |
| 2021 | $10,478,630 |
| 2022 | $12,094,634 |
| 2023 | $11,899,468 |
| 2024 | $9,758,066 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ, Sijani F, Brinkman DJ, et al. · Cancer Treat Rev 2024 · Meta-Analysis, Systematic Review
- Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Hamano J, Higashibata T, Kessoku T, et al. · J Clin Oncol 2024 · Multicenter Study, Randomized Controlled Trial
- A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X, Wang D, Qu X, et al. · Expert Rev Clin Pharmacol 2019 · Review, Network Meta-Analysis
- Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
Wobbe B, Gerner M, Köhne CH · BMJ Support Palliat Care 2024 · Meta-Analysis
- Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M, Ahmad D, Hewlett A · J Gastrointestin Liver Dis 2019 · Meta-Analysis, Systematic Review
- Safety of Naldemedine for Opioid-Induced Constipation - A Systematic Review and Meta-Analysis.
Wobbe B, Gerner M, Köhne CH · J Pain Palliat Care Pharmacother 2025 · Systematic Review, Meta-Analysis
Sponsor: Bdsi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.